Key result
CardioMEMS is feasible and safe in congenital heart disease, but hospitalization benefits remain unproven.
Why the study?
Limited experience exists regarding the use of the CardioMEMS HF System in patients with congenital heart disease.
Does the implantable hemodynamic monitor (CardioMEMS) improve remote management and reduce heart failure hospitalizations in children and adults with complex congenital heart disease?
Does the implantable hemodynamic monitor (CardioMEMS) improve remote management and reduce heart failure hospitalizations in children and adults with complex congenital heart disease?
While percutaneous implantation of the CardioMEMS device is feasible and safe in selected patients with complex congenital heart disease, its efficacy in reducing heart failure hospitalizations requires further multi-center validation.
Supports feasibility and safety in selected congenital heart disease; leaves open efficacy for reducing hospitalizations pending multicenter validation.
The CardioMEMS HF System (Abbott, Abbott Park, IL) is the first FDA- and CE-Mark-approved device for monitoring patients with heart failure, significantly reducing hospitalizations and improving the quality of life for NYHA class III non-congenital adult patients. This device, implanted percutaneously, allows the direct monitoring of pulmonary arterial pressure with the wireless transfer of pressure data to the clinician, who can adjust the therapy remotely. Limited experience exists regarding its use in patients with congenital heart disease (CHD). CardioMEMS device implantation is feasible and safe in selected adults and children with CHD. The potential of the device to reduce heart failure hospitalizations in this population is enormous, but further multi-center studies are needed to demonstrate its efficacy.
No takes yet. Share an insight, caveat, or question.
Piccinelli et al. (2024) conducted a review in Congenital heart disease with advanced heart failure. CardioMEMS HF System was evaluated. CardioMEMS device implantation is feasible and safe in selected adults and children with congenital heart disease, though its efficacy in reducing heart failure hospitalizations remains controversial.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: